Omadacycline (OMC), a broad-spectrum aminomethylcycline, has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections. Here, the in vitro activity of OMC against clinically relevant anaerobes was similar to that of tigecycline, with MIC 90 values of 1 to 8 μg/ml against Bacteroides spp., 0.5 μg/ml against Clostridium difficile , Prevotella spp., and Porphyromonas asaccharolytica , 1 μg/ml against Peptostreptococcus spp., and 16 μg/ml against Clostridium perfringens .
No takes yet. Share an insight, caveat, or question.
Stapert et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: